Patents Represented by Attorney, Agent or Law Firm Incyte Pharmaceuticals, Inc.
  • Human prostate-associated protease
    Patent number: 6043033
    Abstract: The present invention provides a human prostate-associated protease (HUPAP) and polynucleotides which identify and encode HUPAP. The invention also provides expression vectors, host cells, antibodies, antagonists, and antisense molecules. The invention also provides methods for treating disorders associated with expression of HUPAP.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: March 28, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Preeti Lal
  • Human microfibril-associated glycoprotein 4 splice variant
    Patent number: 6037163
    Abstract: The invention provides a human microfibril-associated glycoprotein 4 splice variant (MAG4V) and polynucleotides which identify and encode MAG4V. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of MAG4V.
    Type: Grant
    Filed: August 4, 1999
    Date of Patent: March 14, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Y. Tom Tang, Neil C. Corley, Purvi Shah
  • Human parvulin-like protein
    Patent number: 6037164
    Abstract: The present invention provides a human parvulin-like protein (HPVLP) and polynucleotides which identify and encode HPVLP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPVLP and a method for producing HPVLP. The invention also provides for agonists, antibodies, or antagonists specifically binding HPVLP, and their use, in the prevention and treatment of diseases associated with expression of HPVLP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPVLP for the treatment of diseases associated with the expression of HPVLP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPVLP.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: March 14, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventor: Janice Au-Young
  • Method for detecting HTRAN polynucleotides
    Patent number: 6037132
    Abstract: The present invention provides a human transcription factor (HTRAN) and polynucleotides which identify and encode HTRAN. The invention also provides expression vectors and host cells, agonists, antibodies, or antagonists. The invention provides methods for treating diseases associated with expression of HTRAN.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: March 14, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah
  • ATP synthase subunit homolog
    Patent number: 6036954
    Abstract: The invention provides a human ATP synthase subunit homolog (ASYNT) and polynucleotides which identify and encode ASYNT. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of ASYNT.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: March 14, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Y. Tom Tang, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn
  • Methods for obtaining nucleic acid containing a mutation
    Patent number: 6033861
    Abstract: In order to facilitate the screening of an organism, or a population of organisms, carrying heterozygous mutations for identifying the presence of a mutation in a gene of interest, a method is provided which utilizes mismatch binding proteins, such as MutS. The method comprises the steps of denaturing double stranded nucleic acid present in a nucleic acid sample from an organism; allowing the nucleic acid to anneal; and removing homoduplexes from the annealed sample, thereby retaining heteroduplexes in the sample. A positive signal from a probe specific for the gene of interest indicates that the organism carries a mutation in the gene.
    Type: Grant
    Filed: November 18, 1998
    Date of Patent: March 7, 2000
    Assignee: Incyte Genetics, Inc.
    Inventors: Alan J. Schafer, Jamie W. Foster
  • Human phosphatidylinositol transfer protein gamma
    Patent number: 6034063
    Abstract: The invention provides a new human phosphatidylinositol transfer protein gamma (PITP.gamma.) and polynucleotides which identify and encode PITP.gamma.. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PITP.gamma..
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: March 7, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Human cathepsin
    Patent number: 6033893
    Abstract: The invention provides a new human cathepsin (LCAP) and polynucleotides which identify and encode LCAP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of LCAP.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: March 7, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Karl J. Guegler, Neil C. Corley, Purvi Shah
  • Human macrophage antigen
    Patent number: 6034219
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human macrophage antigen (TMAH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding TMAH. The invention also provides for the use of substantially purified TMAH and its agonists, antibodies, antagonists or inhibitors in pharmaceutical compositions for treatment of diseases associated with expression of TMAH. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the genomic sequence or transcripts encoding TMAH and anti-TMAH antibodies which specifically bind to TMAH.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: March 7, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Janice Au-Young, Surya K. Goli
  • Polynucleotide encoding a novel human cytokine/steroid receptor
    Patent number: 6033869
    Abstract: The present invention provides a human cytokine/steroid receptor protein (CYSTAR) and polynucleotides which identify and encode CYSTAR. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of CYSTAR, as well as diagnostic assays.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: March 7, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Surya K. Goli, Jennifer L. Hillman, Lynn E. Murry
  • Human transmembrane protein
    Patent number: 6033870
    Abstract: The invention provides a novel human integral membrane protein (TMP-2) and polynucleotides which encode TMP-2. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of TMP-2.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: March 7, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah
  • Human ice homolog
    Patent number: 6033848
    Abstract: The present invention provides a polynucleotide (icel) which identifies and encodes a human ice homolog (ICEL) expressed in lung cells and tissues. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified ICEL peptide, antibodies capable of binding to ICEL, inhibitors which bind to ICEL and pharmaceutical compositions based on ICEL specific antibodies or inhibitors. The invention specifically provides for diagnostic assays which identify a disorder or disease with altered icel expression which allows identification and monitoring of hospital patients. These assays utilize icel encoding or controlling nucleic acid sequences, fragments or oligomers thereof, or antibodies specific for the peptide.
    Type: Grant
    Filed: August 1, 1995
    Date of Patent: March 7, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Scott Michael Braxton, Dinh Diep, Jeffrey J. Seilhamer
  • Cyclophilin-type peptidyl-prolyl cis/trans isomerase
    Patent number: 6030825
    Abstract: The invention provides a human cyclophilin-type peptidyl-prolyl cis/trans isomerase (CPCI) and polynucleotides which identify and encode CPCI. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of CPCI.
    Type: Grant
    Filed: August 19, 1998
    Date of Patent: February 29, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley, Karl J. Guegler, Chandra Patterson
  • Antibody for a homolog of rat elastase IV derived from human pancreas
    Patent number: 6030791
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a human homolog of rat elastase IV (HEIV) expressed in pancreas tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode HEIV, hybridization probes or oligonucleotides for the detection of HEIV-encoding nucleotide sequences, and a diagnostic test based on HEIV-encoding nucleic acid molecules. The present invention further provides for genetically engineered host cells for the expression of HEIV, biologically active HEIV, antibodies capable for binding specifically to HEIV, and treatment methods comprising administration of compounds, such antibodies or inhibitors, capable of binding HEIV to alter its activity.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: February 29, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Scott M. Braxton, Dinh Diep, Angelo M. Delegeane
  • Human N-acetylneuraminate lyase
    Patent number: 6030824
    Abstract: The invention provides a human N-acetylneuraminate lyase (HNANL) and polynucleotides which identify and encode HNANL. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HNANL.
    Type: Grant
    Filed: February 1, 1999
    Date of Patent: February 29, 2000
    Assignee: Incyte Pharmaceuticals
    Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley
  • Glutathione S-transferase
    Patent number: 6030809
    Abstract: The invention provides a human new glutathione S-transferase (GSTS) and polynucleotides which identify and encode GSTS. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GS.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: February 29, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley, Purvi Shah
  • Nek1-related protein kinase
    Patent number: 6030801
    Abstract: The invention provides a human Nek 1-related protein kinase (NRPK) and polynucleotides which identify and encode NRPK. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of NRPK.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: February 29, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Neil C. Corley, Karl J. Guegler, Mariah Baughn
  • Human parvulin-like protein
    Patent number: 6030826
    Abstract: The present invention provides a human parvulin-like protein (HPVLP) and polynucleotides which identify and encode HPVLP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPVLP and a method for producing HPVLP. The invention also provides for agonists, antibodies, or antagonists specifically binding HPVLP, and their use, in the prevention and treatment of diseases associated with expression of HPVLP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPVLP for the treatment of diseases associated with the expression of HPVLP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPVLP.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: February 29, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventor: Janice Au-Young
  • Two new WD-40 proteins
    Patent number: 6025464
    Abstract: The invention provides two new WD-40 proteins (WDPro) and polynucleotides which identify and encode WDPro. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of WDPro.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: February 15, 2000
    Assignee: Incyte Pharmaceutials, Inc.
    Inventors: Olga Bandman, Preeti Lal, Neil C. Corley
  • Method for detecting the presence of a polynucleotide encoding a hyaluronan receptor expressed in human umbilical vein endothelial cells
    Patent number: 6025138
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode the hyaluronan receptor (hr) from human umbilical vein endothelial cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode hr, expression vectors for the production of purified HR, antibodies capable of binding specifically to HR, hybridization probes or oligonucleotides for detecting the upregulation of HR encoding nucleotide sequences, genetically engineered host cells for the expression of HR, diagnostic tests for activated, angiogenic, inflamed or metastatic cells and/or tissues based on HR-encoding nucleic acid molecules and antibodies capable of binding specifically to the receptor.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: February 15, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer